Weekly Analysts’ Ratings Changes for Exelixis (EXEL)

Several analysts have recently updated their ratings and price targets for Exelixis (NASDAQ: EXEL):

• 2/4/2026 – Exelixis had its price target raised by analysts at Barclays PLC from $41.00 to $44.00. They now have an “equal weight” rating on the stock.
• 2/4/2026 – Exelixis was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 2/3/2026 – Exelixis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
• 2/2/2026 – Exelixis had its price target raised by analysts at Morgan Stanley from $48.00 to $49.00. They now have an “equal weight” rating on the stock.
• 1/27/2026 – Exelixis had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Exelixis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 1/14/2026 – Exelixis was given a new $51.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – Exelixis had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Exelixis had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $48.00 price target on the stock, up previously from $45.00.
• 1/5/2026 – Exelixis was downgraded by analysts at Citigroup Inc. from a “market outperform” rating to an “underperform” rating.
• 1/5/2026 – Exelixis was given a new $41.00 price target on by analysts at UBS Group AG.
• 1/5/2026 – Exelixis was downgraded by analysts at Bank of America Corporation from a “neutral” rating to an “underperform” rating. They now have a $41.00 price target on the stock.
• 12/18/2025 – Exelixis had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/14/2025 – Exelixis was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.

Insider Activity

In other news, Director Stelios Papadopoulos sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the transaction, the director directly owned 1,189,228 shares in the company, valued at $51,790,879.40. This trade represents a 7.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Dana Aftab sold 48,383 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total value of $2,056,277.50. Following the completion of the transaction, the executive vice president directly owned 664,778 shares in the company, valued at approximately $28,253,065. This trade represents a 6.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 245,235 shares of company stock valued at $10,490,600. Corporate insiders own 2.82% of the company’s stock.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.